Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellectis (CLLS) EBITDA Margin (2016 - 2023)

Historic EBITDA Margin for Cellectis (CLLS) over the last 9 years, with Q3 2023 value amounting to 13336.13%.

  • Cellectis' EBITDA Margin rose 22941600.0% to 13336.13% in Q3 2023 from the same period last year, while for Sep 2023 it was 444.85%, marking a year-over-year increase of 2380500.0%. This contributed to the annual value of 348.56% for FY2022, which is 2586200.0% down from last year.
  • Cellectis' EBITDA Margin amounted to 13336.13% in Q3 2023, which was up 22941600.0% from 13270.22% recorded in Q2 2023.
  • Cellectis' EBITDA Margin's 5-year high stood at 28.75% during Q1 2020, with a 5-year trough of 16856.83% in Q1 2023.
  • For the 5-year period, Cellectis' EBITDA Margin averaged around 3805.73%, with its median value being 870.34% (2019).
  • Its EBITDA Margin has fluctuated over the past 5 years, first soared by 28762700bps in 2019, then tumbled by -151205600bps in 2022.
  • Over the past 5 years, Cellectis' EBITDA Margin (Quarter) stood at 870.34% in 2019, then soared by 67bps to 286.94% in 2020, then soared by 74bps to 74.8% in 2021, then skyrocketed by 53bps to 35.32% in 2022, then tumbled by -37656bps to 13336.13% in 2023.
  • Its last three reported values are 13336.13% in Q3 2023, 13270.22% for Q2 2023, and 16856.83% during Q1 2023.